Sign In

Maryna Kolochavina

Rare and Orphan│Ultra-rare│Pediatrics│Advanced Therapy│Combined Medicinal Products│Omics│ Asset Integrated Lifecycle Management│Asset & Franchise Strategy│Asset & Portfolio Transactions│Patient’s Ecosystem

Maryna Kolochavina is an experienced executive leader in the pharmaceutical industry, specializing in rare and orphan medicinal products. She holds a PharmD and PhD, and is certified as a Project Management Professional (PMP).2

As of February 2025, Maryna has over 18 years of experience in lifecycle asset management for rare and orphan drugs.2 Her expertise spans across:

  1. Managing over 242 rare and orphan medicinal products and advanced therapies
  2. Working with 42 therapeutic classes
  3. Handling 440 orphan drug designations
  4. Contributing to approximately $3.2 billion in capital committed to alliances with biotechnology and pharmaceutical partners2

At Syneos Health, Maryna serves as the Executive Director of Integrated Lifecycle Management for Rare Diseases.13 Her role involves:

  • Planning and executing multiple study phases (pre-clinical to phase IV)
  • Managing various study designs, including registries, compassionate use programs, and safety surveillance studies
  • Overseeing rare Advanced Therapy Medicinal Product (ATMP) and stem cell studies, as well as Omics studies3

Maryna is also an active patient advocate, representing the Patient Voice initiative at Charité in Berlin, Germany.23 She is a member of 14 organizations and sits on one board of directors.2

Her educational background includes a PharmD in clinical pharmacology from Gdansk Medical Academy and translational work in rare skin diseases.3 Maryna holds multiple certifications, including ACRP, BARQA, ASQ, and PMI.3

Highlights

Sep 4 · syneoshealth.com
An Integrated Development Plan in Rare & Orphan Medicinal Products
Sep 24 · xtalks.com
Real-World Data Collection in Early Access Programs - Xtalks
Real-World Data Collection in Early Access Programs - Xtalks
INC Research and inVentiv Health complete merger

Related Questions

What are some of the key projects Maryna Kolochavina has led at Syneos Health?
How has Maryna Kolochavina's work impacted the treatment of rare diseases?
What are Maryna Kolochavina's main responsibilities as Executive Director at Syneos Health?
Can you provide examples of Maryna Kolochavina's achievements in lifecycle management?
How does Maryna Kolochavina's background in biotechnology and clinical pharmacology influence her work?
Maryna Kolochavina
Maryna Kolochavina, photo 1
Maryna Kolochavina, photo 2
Add to my network

Location

Berlin Metropolitan Area